CAR-T cell immune-therapy

CAR-T (Chimeric Antigen Receptor modified T cell therapy) for Acute lymphoblastic leukemia(ALL)

Relapsed and refractory acute lymphoblastic leukemia(ALL) remains to be a significant cause of cancer associated morbidity and mortality for children and adults. CAR-T cell therapy is one of the most promising targeted immune-therapies has received extensive attention which has resulted in multiple applications. CD19 directed CAR T cells have made significant progresses in the treatment of refractory/relapsed ALL, complications still hinder further clinical application.

Biocure has established pre-clinical and clinical designs of 2nd generation CAR-T cell, standard protocol for conditioning and infusion, better control of complications and combination with other therapeutic options.

Pre-clinical study will start early of 2018 and clinical study will start middle of 2018.

CAR-T cell immune-therapy

CAR-T (Chimeric Antigen Receptor modified T cell therapy) for Acute lymphoblastic leukemia (ALL)

  • Relapsed and refractory acute lymphoblastic leukemia(ALL) remains to be a significant cause of cancer associated morbidity and mortality for children and adults
  • CAR-T cell therapy is one of the most promising targeted immune-therapies has received extensive attention which has resulted in multiple applications.
  • CD19 directed CAR T cells have made significant progresses in the treatment of refractory/relapsed ALL, complications still hinder further clinical application
  • Biocure has established pre-clinical and clinical designs of 2nd generation CAR-T cell, standard protocol for conditioning and infusion, better control of complications and combination with other therapeutic options
  • Pre-clinical study has been started Jan of 2018 and clinical study will be started middle of 2018
  • Preliminary clinical application of CD19 CART-T cell was performed in 10 Chinses with complete response rate of 80% in B-ALL
  • Only 30 % of the respondents experienced side effects, cytokine release syndrome (CRS) and fever.
car-t-cell-immune-therapy-01
car-t-cell-immune-therapy-02

Total WW Market Value: Top 10 Products in 2022